Research Library › Neuropeptides
Tesofensine (code NS2330) is a synthetic small molecule of the phenyltropane class, not a peptide, that was designed to inhibit the reuptake of the monoamine neurotransmitters dopamine, noradrenaline and serotonin. It was discovered by the Danish company NeuroSearch, with patent priority in 1996, and its rights passed to Saniona in 2014. As of October 2026 it is not approved by the FDA or any other regulator; a marketing application by Saniona’s partner Medix remains under review in Mexico.
Key facts
| Type | Synthetic small molecule (phenyltropane), not a peptide; formula C17H23Cl2NO |
|---|---|
| Other names | NS2330 |
| First described | Tropane-derivative patent, priority February 1996 (US 6,288,079, granted 2001) |
| Developed by | NeuroSearch A/S, Denmark (inventors Scheel-Krüger, Moldt, Wätjen); partnered with Boehringer Ingelheim; rights to Saniona in 2014 |
| Designed target | Monoamine transporters for dopamine, noradrenaline and serotonin (designed as a triple reuptake inhibitor) |
| Regulatory status (Oct 2026) | Not FDA-approved or approved elsewhere; Medix application under review by COFEPRIS (Mexico) since February 2025 resubmission |
A small molecule, not a peptide
Tesofensine is often listed alongside research peptides, but it is not one. It is a compact synthetic organic molecule built on a tropane ring system, with a dichlorophenyl group and an ethoxymethyl side chain, and a molecular formula of C17H23Cl2NO [1]. It contains no amino acids. It is included in this library only because it appears in supplier catalogs next to peptide products.
Who developed it
Tesofensine was discovered at NeuroSearch A/S, a Danish biotechnology company. A NeuroSearch patent on a series of tropane derivatives, naming Jørgen Scheel-Krüger, Peter Moldt and Frank Wätjen as inventors, has a priority date of February 1996 and was granted in the US in 2001 [1]. NeuroSearch developed the compound, as NS2330, in collaboration with Boehringer Ingelheim [2].
In October 2014 Saniona acquired the rights to tesofensine from NeuroSearch [3]. In 2016 Saniona licensed development and commercial rights for Mexico and Argentina to the Mexican company Productos Medix [4].
What it was designed to target
The NeuroSearch patent describes the tropane series as inhibitors of the reuptake of the monoamine neurotransmitters dopamine, serotonin and noradrenaline, measured in part by binding to the dopamine transporter [1]. A compound that blocks all three transporters is often called a triple reuptake inhibitor. This describes the designed laboratory target, not an effect in people.
Research history
- 1996: Priority date of the NeuroSearch tropane-derivative patent [1]
- 2005: NeuroSearch and Boehringer Ingelheim end plans for Phase 3 in their Alzheimer’s and Parkinson’s programs after mid-stage trials [2]
- 2007: Results of a randomized trial in an early Parkinson’s disease research program published [5]
- October 2014: Saniona acquires tesofensine from NeuroSearch [3]
- 2016: Medix licenses rights for Mexico and Argentina [4]
- 2019: Medix files for marketing authorization in Mexico [4]
Tesofensine was originally investigated in research programs on Alzheimer’s disease and Parkinson’s disease [2, 5]. Development later shifted to a research program on obesity, and Medix completed a Phase 3 program in Mexico [4].
Regulatory status as of October 2026
Tesofensine is not approved by the FDA or by any other regulator. In Mexico, a technical committee of the regulator COFEPRIS gave a non-binding favorable opinion in February 2023, which Saniona stressed was neither an authorization nor a rejection [4]. In November 2024 Saniona reported that the application had not yet been approved [6]. Medix resubmitted a revised application on 20 February 2025, and Saniona’s interim report of 27 August 2026 states that Medix is still working to obtain approval [7, 8].
Tesofensine is not listed in FDA’s May 2026 list of bulk drug substances nominated for 503A compounding [9].
About this reference page
Kalibra Labs does not currently supply Tesofensine. This page is published as a neutral scientific and regulatory reference. Browse the Neuropeptides guide or the FDA Peptide Regulatory Tracker.
Frequently asked questions
Is tesofensine a peptide?
No. Tesofensine is a synthetic small molecule of the phenyltropane class with the formula C17H23Cl2NO; it contains no amino acids [1].
Who developed tesofensine?
It was discovered by the Danish company NeuroSearch, which developed it with Boehringer Ingelheim. Saniona acquired the rights in 2014 [1, 2, 3].
Is tesofensine FDA approved?
No. As of October 2026 tesofensine is not approved by the FDA or any other regulator [7, 8].
Sources
- Scheel-Krüger J, Moldt P, Wätjen F (NeuroSearch A/S). Tropane-derivatives, their preparation and use. US Patent 6,288,079 B1; priority 22 Feb 1996, granted 11 Sep 2001. Link
- Fierce Biotech. Experimental drug fails mid-stage trial for Alzheimer's, Parkinson's (NS2330, NeuroSearch and Boehringer Ingelheim). 9 Aug 2005. Link
- Saniona AB. Saniona buys out payment obligation to NeuroSearch (press release; notes October 2014 acquisition of tesofensine). 4 Jul 2017. Link
- Saniona AB. Saniona's partner Medix receives favorable opinion for tesofensine in Mexico (press release). 25 Feb 2023. Link
- Hauser RA, Salin L, Juhel N, Konyago VL. Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease. Mov Disord. 2007;22(3):359–365. doi:10.1002/mds.21258. Link
- Saniona AB. Mexican application for tesofensine not yet approved (press release). 6 Nov 2024. Link
- Saniona AB. Annual Report 2025 (tesofensine section; Medix resubmission to COFEPRIS 20 Feb 2025). Link
- Saniona AB. Interim report January–June 2026 (Swedish). 27 Aug 2026. Link
- U.S. FDA. Bulk drug substances nominated for use in compounding under section 503A, Categories 1–3 (updated 14 May 2026). Link
Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.
Kalibra Labs does not supply this compound. This page is a scientific, historical and regulatory reference only; it is not medical advice and makes no claim about use in people or animals.
